POU2F2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL82602	0.51	9/20
SCHEMBL2187039	0.44	8/20
SCHEMBL81275	0.50	7/20
SCHEMBL92953	0.48	4/20
SCHEMBL3522619	0.48	4/20
SCHEMBL2186404	0.47	4/20
SCHEMBL3528486	0.43	4/20
SCHEMBL3528387	0.47	3/20
SCHEMBL2186003	0.45	3/20
SCHEMBL3525535	0.41	3/20
SCHEMBL2187245	0.47	2/20
SCHEMBL3527644	0.47	2/20
SCHEMBL965846	0.43	2/20
SCHEMBL1242575	0.38	2/20
Linagliptin (SCHEMBL160188)	1.00	1/20
Linagliptin (SCHEMBL195962)	1.00	1/20
Linagliptin (SCHEMBL637238)	1.00	1/20
SCHEMBL1771687	0.88	1/20
SCHEMBL1771688	0.88	1/20
SCHEMBL638034	0.87	1/20

Clinical trials — most relevant to POU2F2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome	PHASE4	WITHDRAWN
Mechanisms of Lipodystrophy in HIV-Infected Pateints	PHASE4	COMPLETED
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation	PHASE2/PHASE3	UNKNOWN
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	PHASE1/PHASE2	SUSPENDED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
Natural History Study of GATA2 Deficiency and Related Disorders	nan	RECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls.	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
The Role of TBX3 in Human ES Cell Differentiation	nan	WITHDRAWN
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Natural History of Thyroid Function Disorders	nan	RECRUITING
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Otoferlin Patient Registry and Natural History Study	nan	RECRUITING
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED
Family Resilience Initiative Research Program	nan	UNKNOWN
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases	nan	RECRUITING
MR Elastography in Intracranial Lesions: Feasibility & Accuracy	nan	ACTIVE_NOT_RECRUITING
Azoospermia Patients	nan	RECRUITING
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α.	nan	UNKNOWN
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS	nan	RECRUITING
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Exome Analysis in Hearing Impaired Patients	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Association of Formaldehyde Exposure to Myeloid Leukemia in Workers in Guangdong, China	nan	COMPLETED
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a POU2F2 binder may also engage these)

Protein	Name	Similarity
Q29013	—	1.000	Q29013 →
P31362	—	1.000	P31362 →
Q00196	—	1.000	Q00196 →
P42571	—	1.000	P42571 →
P62515	—	0.999	P62515 →
P49335	—	0.998	P49335 →
P62516	—	0.998	P62516 →
P23899	—	0.997	P23899 →
P22361	—	0.997	P22361 →
Q90867	—	0.996	Q90867 →
Q90270	—	0.996	Q90270 →
P24610	—	0.996	P24610 →
P20823	—	0.995	P20823 →
Q03365	—	0.995	Q03365 →
Q58NQ4	—	0.995	Q58NQ4 →
P27889	—	0.995	P27889 →
Q80TZ9	—	0.995	Q80TZ9 →
Q812B1	—	0.994	Q812B1 →
O95096	—	0.994	O95096 →
P35680	—	0.994	P35680 →
P20912	—	0.994	P20912 →
Q9H334	—	0.994	Q9H334 →
Q62255	—	0.994	Q62255 →
Q98876	—	0.994	Q98876 →
P31363	—	0.994	P31363 →
Q5RER5	—	0.994	Q5RER5 →
P25425	—	0.993	P25425 →
P48031	—	0.993	P48031 →
Q6F2E4	—	0.993	Q6F2E4 →
A2D4R4	—	0.993	A2D4R4 →